Premium
Control of Systemic and Local Inflammation with Transforming Growth Factor β Containing Formulas
Author(s) -
Fell John M.E.
Publication year - 2005
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/01486071050290s4s126
Subject(s) - ileum , medicine , cytokine , proinflammatory cytokine , enteral administration , crohn's disease , transforming growth factor , inflammation , gastroenterology , intestinal mucosa , interleukin , parenteral nutrition , immunology , disease
Enteral nutrition therapy with liquid diet has been shown to be effective in achieving clinical remission in intestinal Crohn's disease. The mechanism of action of this therapy, however, is still poorly understood. As part of our assessment of the action of 3 related polymeric enteral therapies, we have used a variety of techniques to document the histological and cytokine responses, in the mucosa and, systemically, to these treatments. The feeds studied (AL110, Modulen IBD and ACD004 [Nestle, Vevey, Switzerland]) all have casein as the protein source, are lactose free and are rich in transforming growth factor β (TGF‐β). They have all been shown to induce clinical remission associated with mucosal healing. In the case of Modulen IBD, as well as mucosal macroscopic and histological healing there was a fall in mucosal proinflammatory cytokines: interleukin‐1 mRNA in colonic and ileal, interleukin‐8 mRNA in the colon and interferon 7 mRNA in the ileum, but a rise in the regulatory cytokine TGF‐β mRNA in the ileum. These results indicate that these formulas are influencing the disease process itself, and thus suggest that the clinical remission achieved is a result of a reduction in inflammation, rather than a consequence of some other nutrition effect.